Proteins and Peptides

17 Aug 2017 Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7
15 Aug 2017 U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial
10 Aug 2017 Bonti Announces Topline Results of EB-001 Phase 2A Clinical Study in Glabellar Lines
10 Aug 2017 Allegro Ophthalmics Announces Positive Topline Results from DEL MAR Phase 2b Stage 2 Trial Evaluating Luminate® in Patients with Diabetic Macular Edema
04 Aug 2017 Portola Pharmaceuticals Announces Resubmission of Biologics License Application for AndexXa® (Andexanet Alfa)
02 Aug 2017 Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute Radiation Syndrome
01 Aug 2017 Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS™ (eflapegrastim), a Novel Long-Acting GCSF
27 Jul 2017 Novo Nordisk A/S: Victoza® has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events
24 Jul 2017 Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
24 Jul 2017 Stealth BioTherapeutics Initiates Phase 2/3 Study of Elamipretide in Patients With Barth Syndrome
22 Jul 2017 Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
21 Jul 2017 Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompé Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy
20 Jul 2017 Merck Announces U.S. FDA Grants Tentative Approval for LUSDUNA™ Nexvue™ (insulin glargine injection), a Follow-On Biologic Basal Insulin
20 Jul 2017 Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sepsis
19 Jul 2017 Evolus Announces FDA Acceptance for Review of the Biologics License Application for DWP-450 Neuromodulator
19 Jul 2017 Bioniz Therapeutics Reports Top-Line Phase 1 Clinical Study Results for BNZ-1, A Novel Multi-Cytokine Inhibitor
19 Jul 2017 Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan
18 Jul 2017 Ember Therapeutics Announces Publication in Circulation of Data Validating Utility of BMP-7 to Regulate Scar Formation in the Heart
18 Jul 2017 Proclara Biosciences Presents New Preclinical Data Supporting the Development of NPT189 at Alzheimer’s Association International Conference (AAIC) 2017
15 Jul 2017 Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label
14 Jul 2017 Mallinckrodt Phase 3 Terlipressin Trial Achieves its Enrollment Target Ahead of Schedule
14 Jul 2017 Initiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy
13 Jul 2017 Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
11 Jul 2017 Prometic Announces Positive Long Term Clinical Data on Ryplazym™ in Plasminogen Congenital Deficiency and Provides Regulatory Update
11 Jul 2017 BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing